Central retinal thickness following panretinal photocoagulation using a multispot semi-automated pattern-scanning laser to treat ischaemic diabetic retinopathy: Treatment in one session compared with four monthly sessions

Archive ouverte

Gabrielle, Pierre Henry | Massin, Pascale | Kodjikian, Laurent | Erginay, Ali | Pallot, Charlotte | Jonval, Lysiane | Soudry, Agnès | Couturier, Aude | Vardanian-Vartin, Cristina | Bron, Alain M. | Creuzot-Garcher, Catherine

Edité par CCSD ; John Wiley -

National audience. PURPOSE: To compare central retinal thickness (CRT) after panretinal photocoagulation (PRP) with a multispot semi-automated PAttern-SCAnning Laser (PASCAL) in one session (SS-PRP) versus four monthly sessions (MS-PRP) in diabetic retinopathy. METHODS: Multicentre, prospective, randomized, single-blinded, controlled trial evaluating the noninferiority of SS-PRP versus MS-PRP for CRT measured with macular spectral-domain optical coherence tomography (SD-OCT), with a 9-month follow-up in patients presenting severe nonproliferative diabetic retinopathy (DR) or mild proliferative DR without macular oedema (ME) at baseline. RESULTS: Ninety-seven eyes of 97 participants with a mean age of 57.0 +/- 14.2 years were included. The mean change of CRT from baseline to 9 months was not statistically different in SS-PRP or in MS-PRP: +16.9 +/- 28.3 mum versus +24.7 +/- 31.8 mum, respectively (p = 0.224). The variation in mean best-corrected visual acuity (BCVA) from baseline to 9 months was similar in both groups: -1.1 +/- 6.5 letters versus -0.6 +/- 6.2 letters (p = 0.684). The number of patients with stabilization of DR was not statistically different between the two groups. No severe complication was recorded in either group. CONCLUSION: This study showed the noninferiority of PRP performed in one session versus four monthly sessions with a PASCAL concerning central retinal thickness for treating mild proliferative or severe nonproliferative DR without ME at baseline.

Consulter en ligne

Suggestions

Du même auteur

Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?

Archive ouverte | Gabrielle, Pierre-Henry | CCSD

Corresponding author: catherine.creuzot-garcher@chu-dijon.fr. International audience. Refers toIntravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non...

Role of 24-S-hydroxycholesterol in membrane dynamics during retinal gliosis in glaucoma

Archive ouverte | Gabrielle, Pierre Henry | CCSD

International audience. Purpose : Glaucoma is a severe and irreversible ocular disease characterized by progressive optic neuropathy with the loss of retinal ganglion cells (RGC). One of the established causes of RG...

Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective multicenter study involving 804 patients [Letter to the Editor (by invitation)]

Archive ouverte | Meillon, Cyril | CCSD

Letter to the Editor (by invitation).. International audience

Chargement des enrichissements...